Cellectis S.A. (CLLS)
Develops gene-edited immune cells to treat blood cancers and solid tumors.
$2.84+0.00%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-3.7%
The outlook
Cellectis trades well below both its 50- and 200-day moving averages, sitting near the lower end of its 52-week range. Analyst consensus leans bullish with an average price target about 168% above the current level, though coverage is modest at five analysts. The stock's overall profile reflects significant disconnect between near-term price weakness and longer-term analyst sentiment.
What’s behind the score
Analyst consensusBuy — 1.8 avg of 5 analysts
Price trendBelow its 50- & 200-day averages
52-week range13% of the way from its 52-week low to high
Price targetAvg target +168% vs current price
Analyst price target
~12-month · 5 analysts$7.60average target+167.6% vs now
Now $2.84
Low $4.00High $10.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$286.0M
52-wk high
$5.48
52-wk low
$2.43
50-day avg
$3.14
200-day avg
$3.78
Trailing P/E
—